NasdaqGS:BMEABiotechs
A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise
Biomea Fusion (BMEA) has completed a $25 million equity offering following the release of data from its Phase II COVALENT-111 trial. The study showed sustained HbA1c reduction in type 2 diabetes patients.
See our latest analysis for Biomea Fusion.
Biomea Fusion’s stock has been notably volatile. Shares initially jumped on the back of encouraging Phase II clinical data, but quickly reversed and dropped sharply after the $25 million equity offering was announced. With the latest share price at...